PAR share price, P/E, ROE & financials

Par Drugs And Chemicals (PAR) had a P/E of 10.2× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 39% below their 52-week high. Sales and net profit grew 2.6% and 5.0% a year over 3 years, with ROCE of 15% and ROE of 12%. It is a small-cap company with a market cap of ₹134 Cr, ranked 107th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 13% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Mar 2026.How we calculate this

past year

Open: ₹111.48
Day high: ₹111.48
Day low: ₹108.10
Prev. close: ₹111.80
Volume: 2.6K

Health check

1 good · 1 fair · 3 to check

ReturnsBehind
+12.8% over a year, better than 2 of 7 peers.
Price tagCheaper
P/E 10.2 vs industry 28.7.
GrowthSlow
Sales +2.6%, profit +5.0% a year over 3 years.
ProfitabilityAverage
ROCE 15.0% vs peer median 17.9%.
Balance sheetn/a
Balance sheet figures aren’t reported.
Red flags3 to check
Quarterly profit down 48.3% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹134 Cr, #107 of 154 in its industry by size.

Defensive

Beta 0.43 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Mar 2026: sales ₹108 Cr · profit ₹13 Cr

Market cap: ₹134 Cr; Small cap
P/E: 10.2; Industry 28.7
Price to book: 1.12; Peers 4.99
Dividend yield: 0.00%
ROE: 11.5%; Peers 14.7%
ROCE: 15.0%; Peers 17.9%
Debt to equity: n/a; Debt ₹0.00 Cr
EPS (TTM): ₹10.65; Face value ₹10
OPM (TTM): 16.5%; Net margin 12.1%
Sales growth: −12.2%; Latest quarter vs a year ago
Profit growth: −48.3%; Latest quarter vs a year ago
Price to sales: 1.25; EV/EBITDA 5.3

Strengths

P/E of 10.2 against an industry P/E of 28.7.
Positive operating cash flow in each of the last 4 years.

Risks to check

Quarterly profit down 48.3% on a year ago.
Quarterly sales down 12.2% on a year ago.
39% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Par Drugs And Chemicals

Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, magnesium aluminometasilicate, magnesium aluminosilicate-USP,…

Headquarters: Vadodara
Employees: 118
Sector: Healthcare
ISIN: INE04LG01015
Website: pardrugs.com

Price range

52 weeks

₹78.05₹180.00

Today

₹108.10₹111.48

Avg volume (3M): 65.5K
1-year return: plus 12.8%
From 52-week high: minus 39.4%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
PARPar Drugs And Chemicals	109.00	minus 2.50%	134	10.2	1.12	–	11.0%	17.3%	–	–	0.00%	plus 12.8%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore · latest reported Mar 26

SalesSelect a row below to chart it

Mar 25	Jun 25	Sep 25	Dec 25	Mar 26
22.3	26	28.7	29.3	19.6
19.9	22.5	22.6	23.3	18.2
2.4	3.6	6.1	6.1	1.4
10.9%	13.7%	21.2%	20.7%	7.4%
0.8	1.8	0.5	1.3	0.4
0	0	0.1	0	0
0.9	0.9	0.9	0.9	0.9
2.3	4.5	5.6	6.4	0.8
27.5%	25.7%	25.6%	25.5%	−2.7%
1.7	3.3	4.1	4.8	0.9
1.34	2.70	3.36	3.90	0.69

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +2.6%
Profit CAGR 3Y: +5.0%
ROE: 11.5%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
95.1	95.1	101	103
–	0.0%	+5.7%	+2.2%
77.3	71.5	81.2	86.3
17.8	23.6	19.3	16.5
18.7%	24.8%	19.2%	16.1%
0.4	0.5	2.3	4.5
0	–	–	–
3.2	3.4	3.6	3.7
0.2	−1.1	0	0
15.1	19.5	17.9	17.3
24.8%	25.7%	25.5%	24.2%
11.3	14.5	13.4	13.1
–	+27.9%	minus 7.9%	minus 1.9%
9.21	11.78	10.86	–

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
12.3	12.3	12.3	12.3
58.9	73.3	86.7	99.7
17.6	16	20.4	17.2
88.9	102	119	129
38.7	41.3	38.9	37.2
0.2	0	–	0.7
0	0	25.1	27.1
22.2	36.7	27.6	41.8
27.7	23.6	27.8	22.4
88.9	102	119	129

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
13.4	20.2	16.2	16.4
−7.3	−5.8	−25.2	−2.2
−0	–	–	–
6	14.4	−9.1	14.3
−7.6	−6.1	−1.2	−2
5.7	14.2	14.9	14.5

Shareholding pattern

Source: NSE filings

73.4%

promoters

Promoters73.41%
Public26.59%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	73.41%	26.59%	0.00
30 Jun 2026	73.41%	26.59%	0.00
31 Mar 2026	73.41%	26.59%	0.00
31 Dec 2025	73.41%	26.59%	plus 0.04
30 Sep 2025	73.37%	26.63%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you